EASD 2019: Risk-Modifying, Rather Than Merely Glucose-Lowering, Therapy Is Urged for Type 2 Diabetes
Results of the DECLARE-TIMI 58 trial point to a need for action.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.